Amgen’s Oncology segment
In 2017, Amgen’s (AMGN) leading oncology drug, Kyprolis, is expected to continue to be a dominant player in the second-line MM (multiple myeloma) space based on data released from two Phase 3 trials, Endeavour and Aspire. The company is also striving to expand Kyprolis’s label in first-line MM to compete more aggressively with MM players like Celgene (CELG), Johnson & Johnson (JNJ), and Bristol-Myers Squibb (BMY).
Notably, the iShares Nasdaq Biotechnology ETF (IBB) has ~8.2% of its total portfolio in AMGN.
On October 20, 2016, Amgen announced positive top-line results from its Phase 3 trial, which compared Xgeva with zoledronic acid, in their efficacy to prevent SREs (skeletal-related events) in patients suffering from MM. The company plans to submit an application to the FDA (US Food and Drug Administration) seeking approval for Xgeva for this new indication in 2017.
To know more about Xgeva, please refer to Market Realist’s “Xgeva: Focusing on Skeletal-Related Events in Cancer Patients.”
Amgen is also actively involved in introducing a new formulation of oprozomib, a novel proteasome inhibitor, to the clinic in 2017. Oprozomib is expected to strengthen Amgen’s MM portfolio going forward.
Blincyto has already been approved by the FDA as therapy for patients suffering from Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Amgen plans to test the efficacy of this drug both as monotherapy as well as in combination with Keytruda in diffuse large B-cell lymphoma.
To know more about Blincyto, please refer to Market Realist’s “Amgen Launches Blincyto Targeting Rare Disease.” Continue to the next part of this series for a closer look at Amgen’s bone health franchise.